FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”

Gene-focused biotech bluebird bio (NASDAQ:BLUE) continues to experience prolonged difficulties in moving its flagship LentiGlobin immunotherapy for beta-thalassemia (a blood disorder that leads to lack of oxygen) to market in the U.S., leading many to question the company's fluency in regulatory operations. Meanwhile, clinical trial delays caused by the pandemic have thrown bluebird's drug development timetables off by many months.